Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Sanofi - Aventis Groupe

< Previous 1 2 3 4 Next >
Press Release: Dupixent® significantly reduced COPD exacerbations in second positive Phase 3 trial, accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Specialty Care growth, strong launch uptake of Beyfortus® and ALTUVIIIO® drive solid Q3 results
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi Enters Next Chapter of Play to Win Strategy
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi delivers first medicines from Global Health Unit’s Impact brand portfolio
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: TZIELD® Phase 3 data presented at ISPAD shows potential to slow the progression of Stage 3 type 1 diabetes in newly diagnosed children and adolescents; full data simultaneously published in The NEJM
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Late-breaking amlitelimab Phase 2b data presented at EADV show potential best-in-class profile in atopic dermatitis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi and Teva announce exclusive collaboration to deliver inflammatory bowel disease treatment
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Once-weekly ALTUVIIIO® approved in Japan as a new class of factor VIII therapy for hemophilia A
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi supporting vulnerable communities as part of commitment to social impact and fight against climate change
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi announces changes to its Executive Committee
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: U.S. CDC Advisory Committee unanimously recommends routine use of Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press release: Online availability of Sanofi’s half-year financial report for 2023
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi to acquire Qunol®, a fast-growing U.S. brand in the healthy aging segment
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Solid Q2 performance and strong pipeline momentum, Full-year 2023 business EPS guidance raised
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA approves Beyfortus™ (nirsevimab-alip) to protect infants against RSV disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Vaccines R&D pipeline raises the bar in RSV, influenza, meningitis, and pneumococcal disease
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive topline Phase 2b data in atopic dermatitis support amlitelimab as a potential first and best-in-class novel investigational anti-OX40-ligand monoclonal antibody
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: ALTUVIIIO late-breaking data at ISTH demonstrates highly effective bleed protection in children with severe hemophilia A with once-weekly dosing
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Availability of the Q2 2023 Memorandum for modelling purposes
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi prevails in Zantac arbitration initiated by Boehringer Ingelheim
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi “all in” on artificial intelligence and data science to speed breakthroughs for patients
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: FDA Advisory Committee unanimously recommends nirsevimab as first immunization against RSV disease for all infants
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi launches 2023 global Employee Stock Purchase Plan
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Positive Phase 2 data of novel investigational anti-CD40L antibody frexalimab show significantly reduced disease activity in relapsing multiple sclerosis
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Annual General Meeting of May 25, 2023 – Frédéric Oudéa new Chairman of the Board of Directors
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Dupixent® (dupilumab) late-breaking Phase 3 COPD results presented at ATS and simultaneously published in the New England Journal of Medicine
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Nirsevimab delivers 83% reduction in RSV infant hospitalizations in a real-world clinical trial setting
From Sanofi - Aventis Groupe
Via GlobeNewswire
Press Release: Sanofi completes acquisition of Provention Bio, Inc.
From Sanofi - Aventis Groupe
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.